Penn Capital Management Company, LLC Biomarin Pharmaceutical Inc Transaction History

Penn Capital Management Company, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$80.93 - $108.63 $76,964 - $103,307	-951 Reduced 3.39%	27,077 $2.84 Million
Q3 2022 Dec 09, 2022	BUY	$82.16 - $96.94 $449,086 - $529,874	5,466 Added 24.23%	28,028 $2.41 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $1.45 Million - $1.71 Million	17,665 Added 360.73%	22,562 $1.95 Million
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $64,760 - $78,686	906 Added 22.7%	4,897 $406,000
Q1 2022 May 17, 2022	SELL	$74.28 - $92.69 $1,411 - $1,761	-19 Reduced 0.47%	3,991 $308,000
Q4 2021 Feb 17, 2022	SELL	$71.72 - $91.47 $7,674 - $9,787	-107 Reduced 2.6%	4,010 $354,000
Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $9,346 - $10,683	-125 Reduced 2.95%	4,117 $318,000
Q2 2021 Aug 16, 2021	BUY	$75.51 - $84.79 $54,442 - $61,133	721 Added 20.48%	4,242 $354,000
Q1 2021 May 13, 2021	BUY	$74.73 - $90.69 $4,633 - $5,622	62 Added 1.79%	3,521 $266,000
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $251,157 - $312,001	3,459 New	3,459 $303,000

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Penn Capital Management Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Penn Capital Management Company, LLC with notifications on news.